Zum Hauptinhalt springen

Hämolytisch-urämisches Syndrom

HUS

Medizinische Fachkräfte

Fachartikel sind für die Nutzung durch Gesundheitsfachkräfte konzipiert. Sie werden von britischen Ärzten verfasst und basieren auf Forschungsergebnissen, britischen und europäischen Richtlinien. Möglicherweise finden Sie einen unserer Gesundheitsartikel nützlicher.

Dies ist eine meldepflichtige Krankheit im Vereinigten Königreich. Siehe die Meldepflichtige Krankheiten Artikel für mehr Details.

Was ist das hämolytisch-urämische Syndrom?

First described in 1955, haemolytic uraemic syndrome (HUS) is thrombotic microangiopathy causing a triad of:

  • Microangiopathic haemolytic anaemia.

  • Thrombozytopenie.

  • Akutes Nierenversagen.

Haemolytic uraemic syndrome is one of the most common causes of acute kidney injury in children.

There are 3 sub-types of haemolytic uraemic syndrome:1

Typical HUS is also known as STEC-HUS. It is most commonly associated with Escherichia coli - historically E coli 0157:H7 has been the most prevalent cause but, at the time of writing, E Coli 026:H11 has become the most common cause. E coli produces a toxin called Shiga toxin, hence, its alternative name of Shiga toxin-producing E. coli (STEC). Historically this was also known as verotoxin-producing E. coli (VTEC). Shiga toxin caused by Shigella dysenteriae causes a similar disease to STEC, but that symptoms are much more severe, and the fatality rate of HUS caused by Shigella dysenteriae is much higher. Salmonella can also be associated with STEC-HUS.

Atypical HUS (aHUS) is caused by an atypical activation of the complement pathway; 60% of people with aHUS have a genetic mutation resulting in abnormal action of the complement genes. A second factor, such as infection, is usually required to produce aHUS.2

Secondary HUS is caused by multiple insults, usually infection. The commonest infective cause is Strep pneumoniae but enterobacteria, Staphylococcus aureus, Epstein-Barr virus, cytomegalovirus, influenza virus, HIV, and SARS-CoV-2 have all been implicated.

Haemolytic uraemic syndrome is a systemic disease caused by damage arising from the circulating toxin which binds to endothelial receptors, particularly in the renal, gastrointestinal and central nervous systems. Thrombin and fibrin are deposited in the microvasculature. This occurs early in the disease, prior even to the development of HUS and may be why antibiotics confer no benefit. Erythrocytes are damaged as they pass through partially occluded small vessels and subsequent haemolysis occurs. Platelets are sequestered but without the cascade of clotting factors as in disseminated intravascular coagulation (DIC).3

Epidemiologie 1

  • Haemolytic uraemic syndrome is more common in children under the age of 10, with most cases occurring in children under the age of 5.

  • Worldwide the incidence of STEC-HUS is 43 illnesses per 100,000 people per year. In the United States, studies have shown the incidence to be 3 per 100,000 children per year in children aged 6 months to 2 years.

  • 15% of children who have presented to an emergency department with bloody diarrhoea have been shown to develop STEC-HUS.

  • A retrospective study of paediatric STEC cases entered into the Public Health England National Enhanced Surveillance System found that, between 2011 and 2014, a fifth of such cases (207 out of 1,059) progressed to HUS. The odds of progression were highest in girls between 1 and 4 years of age but there was no association with rurality or socio-economic status.4

  • In 2018, questionnaires were sent to a total of 607 confirmed cases of STEC O157 reported in England and Wales. 2% (14) were hospitalised for HUS. Most were under 5 years old (median age 3.7).5

  • Incidence is higher between April and September when cattle are more likely to be colonised with STEC (cattle are asymptomatic carriers).

  • About 10% of HUS cases are aHUS. Patients without evidence of underlying infection should be fully investigated, in particular looking for complement gene mutations.6

  • STEC was first reported in the United States of America in 1982. Very large outbreaks of STEC infection have been reported in Japan and Germany; smaller outbreaks have occurred all over the world.7

  • The incidence is significantly higher in cultures which eat raw meat, for example, in Argentina. 7

  • Outbreaks have been associated with failures of food safety standards. The most recent outbreak in England, in 2019, was associated with milk pasteurisation failures.8

Risikofaktoren179

  • Rural populations > urban populations.

  • Warme Sommermonate (Juni-September).

  • Junges Alter (6 Monate bis 5 Jahre).

  • Ältere Menschen oder Personen mit verändertem Immunsystem.

  • Kontakt mit Nutztieren.

  • Intake of contaminated food including raw, processed or undercooked meat, unpasteurised juice or milk products, cross-contamination of food products and utensils, intake of contaminated water, unwashed vegetables.

  • Recent treatment with some chemotherapeutic agents, ciclosporin, or quinine.

  • Schwangerschaft.

Präsentation19

Infection with STEC results in profuse diarrhoea (often but not always bloody), abdominal pain, and sometimes fever and vomiting.

Haemolytic uraemic syndrome normally begins 5-13 days after the diarrhoea starts (most typically at around 7 days). Symptoms then include:

  • Renal findings, such as anuria, oliguria, and fluid overload.

  • Symptoms related to anaemia, such as syncope, fatigue, and pallor.

  • Symptoms related to thrombocytopaenia, such as petechiae and easy bleeding.

In patients with aHUS, symptoms are often more non-specific with fatigue, pallor, or somnolence progressing to signs of acute kidney injury, including oliguria, uraemia, and fluid overload. However, profuse diarrhoea can also be present in aHUS.

In patients with secondary HUS, symptoms include those of the initial infection, such as pneumonia or meningitis.

In adults, HUS is uncommon but, where it does occur, usually during food-related outbreaks, symptoms are more unpredictable and neurologic symptoms such as confusion, seizures, neuropsychiatric symptoms, and coma are markedly more prevalent than in children.

Although HUS is primarily a renal disease, it affects every system. 20% of patients have extra-renal symptoms, including:

  • Neurological: Coma, stroke, seizures, blindness, and confusion all carry a poor prognosis.

  • Pulmonary: Pulmonary hypertension and haemorrhage are rare effects of HUS.

  • Gastrointestinal: As well as the bloody diarrhoea which is common with all HUS, pancreatitis, liver dysfunction, bowel ischemia, and bowel perforation can also occur, particularly with STEC-HUS.

  • Cardiac: Myocardial infarction, pulmonary hypertension, heart failure, hypertension, and peripheral vascular disease can all occur in HUS.

  • Dermatological: Ulcerative skin lesions, and gangrene have been reported.

  • Musculoskeletal: Rhabdomyolysis is a rare complication.

Untersuchung19

Assessment should include:

  • FBC and film: evidence of haemolysis, anaemia, and thrombocytopenia. Raised white cell count and low platelet count are early indicators of development of HUS. Features of microangiopathic haemolysis include falling haemoglobin, fragmented red cells on blood film examination, and low or falling platelet count.

  • Nierenfunktion und Elektrolyte: Ein Anstieg von Harnstoff und Kreatinin kann auf Dehydration zurückzuführen sein, weist jedoch in Verbindung mit Hämolyse und Thrombozytopenie auf den Beginn eines HUS hin.

  • Leberfunktionstests (LFTs).

  • Laktatdehydrogenase (LDH): Ein hoher LDH-Wert ist ein früher Indikator für HUS.

  • CRP.

  • Gerinnungsstatus (verringerte Werte können bei aktivem HUS beobachtet werden).

  • Amylase.

  • Stool testing for E. coli or other bacteria.

  • Urin: Urinanalyse (Hämaturie oder Proteinurie treten früh bei HUS auf); Urin wird zur Kultur ins Labor geschickt.

These investigations should be repeated if any clinical deterioration occurs. Whenever atypical HUS is suspected, further specialist tests are warranted, including:6

  • Mutationsanalyse spezifischer Komplementgene.

  • Von-Willebrand-Faktor-spaltende Protease - ADAMTS13 - Aktivität.

Differentialdiagnose

Beinhaltet:

  • Andere Ursachen für Bauchschmerzen und Durchfall - z. B. akute Gastroenteritis, Appendizitis, entzündliche Darmerkrankung, Inversion.

  • DIC, vielleicht mit Sepsis.

  • HELLP-Syndrom (= Haemolysis, Elevated LLeberenzyme, Niedriger Phrombozytenzahl).

  • Eine autosomal dominante Form des HUS existiert mit einer Anomalie des ADAMTS13-Gens, das für das von-Willebrand-Faktor. It tends to present in childhood.10

  • Erbliche Anomalien der Komplementregulation.

  • Thrombotisch-thrombozytopenische Purpura (was thrombotische Mikroangiopathie verursachen kann).

Behandlung und Management des hämolytisch-urämischen Syndroms11

Siehe auch das separate Escherichia Coli O157 Artikel.

  • Infectious bloody diarrhoea, HUS or the isolation of a VTEC must be reported promptly by telephone to the local Health Protection Team. Local guidance should be followed (the UK guidance is above).

  • Currently, the treatment of STEC-HUS remains purely supportive, with no evidence for specific treatments. General management includes appropriate fluid and electrolyte management, antihypertensive therapy and dialysis where required. Circulating volume must be kept up to protect the kidneys; simply replacing losses with crystalloid and keeping up with faecal loss is inadequate, as circulating volume will be lost by vascular leakage. Where kidney failure occurs, indications for dialysis are as for any other cause of acute kidney failure. Half of all patients require dialysis and this has been linked to inadequate fluid replacement.1

  • In aHUS, complement inhibition with eculizumab is the first-line treatment, and plasma exchange is considered a second-line or adjunctive therapy.12 Whilst eculizumab is approved by NICE, it requires specific conditions to be in place (management in a specialist centre with reporting capabilities). Kidney transplant is often required in aHUS though aHUS can recur in the transplanted kidney.

  • Secondary HUS is treated by managing the underlying condition. There is some evidence of benefit from eculizumab in pregnancy-related HUS.

Prognose1

  • Typical HUS with a diarrhoeal prodrome usually has a good prognosis. Only one death in a patient with STEC-associated HUS was reported in the 2018 Public Health England data analysis.13

  • Other data suggests a mortality of up to 5%.

  • Fatality is highest in the elderly.

  • Although most people make a full recovery, up to 25% develop permanent renal sequelae including worsening renal function, proteinuria, and hypertension. The strongest predictor for ongoing renal impairment is the length of time spent on dialysis.

  • Atypical HUS has historically had a poorer prognosis but the introduction of eculizumab has resulted in reduction of mortality from 50% to 9% in children and 60% to 15% in adults.

Prävention1

  • Proper hand washing after handling raw foods, using the bathroom, or coming into contact with animals, such as at petting farms and zoos, is essential.

  • Unpasteurised dairy products should be avoided.

  • Beef should be cooked thoroughly, especially when minced.

  • Raw and cooked foods should be kept separately.

  • Parents and carers should be alert to "red flags" following a diarrhoeal illness - these include decreased urine output, pallor, fatigue, oedema, or unexplained bruising.

Exklusive Updates für medizinisches Fachpersonal

Bleiben Sie informiert mit den neuesten klinischen Updates, professionellen Einblicken und evidenzbasierten Leitlinien. Der Patient Pro-Newsletter stellt wesentliche Inhalte für Gesundheitsfachkräfte zusammen – direkt in Ihren Posteingang geliefert.

Bitte geben Sie eine gültige E-Mail-Adresse ein

Durch das Abonnieren akzeptieren Sie unsere Datenschutzrichtlinie. Sie können sich jederzeit abmelden. Wir verkaufen Ihre Daten niemals.

Weiterführende Lektüre und Referenzen

  1. Rout P, Daley SF; Hemolytic Uremic Syndrome.
  2. Atypical hemolytic uremic syndrome; P Walsh and D Kavanaugh; The Journal of Allergy and Clinical Immunology
  3. Tarr PI, Gordon CA, Chandler WL; Shiga-Toxin-produzierende Escherichia coli und hämolytisch-urämisches Syndrom. Lancet. 2005 Mar 19-25;365(9464):1073-86.
  4. Adams N, Byrne L, Rose T, et al; Soziodemografische und klinische Risikofaktoren für das pädiatrische typische hämolytisch-urämische Syndrom: retrospektive Kohortenstudie. BMJ Paediatr Open. 17. Dez 2019;3(1):e000465. doi: 10.1136/bmjpo-2019-000465. eCollection 2019.
  5. Shiga-Toxin-produzierende Escherichia coli (STEC) Daten: 2018, aktualisiert 2020; Öffentliche Gesundheit England
  6. Johnson S, Taylor CM; Was gibt es Neues beim hämolytisch-urämischen Syndrom? Eur J Pediatr. 2008 Sep;167(9):965-71. Epub 2008 Jun 25.
  7. Hämolytisch-urämisches Syndrom; D Karpman et al; Journal of Internal Medicine
  8. Jenkins C, Bird PK, Wensley A, et al; Outbreak of STEC O157:H7 linked to a milk pasteurisation failure at a dairy farm in England, 2019. Epidemiol Infect. 2022 May 18;150:e114. doi: 10.1017/S0950268822000929.
  9. Hämolytisch-urämisches Syndrom; BMJ Best Practice
  10. Thrombotisch-thrombozytopenische Purpura, Angeboren, TTP; Online-Mendelsche-Erbfolge beim Menschen (OMIM)
  11. Vorläufige betriebliche Gesundheitsrichtlinien für Shiga-Toxin-produzierende Escherichia coli (STEC); Public Health England, 2018
  12. Eculizumab for treating atypical haemolytic uraemic syndrome; NICE 2015
  13. Escherichia coli (E. coli): Anleitung, Daten und Analyse; UK Gesundheitsbehörde, August 2014 - zuletzt aktualisiert Oktober 2017.

Artikelverlauf

Die Informationen auf dieser Seite werden von qualifizierten Klinikern verfasst und begutachtet.

Online-Apotheke, Behandlungen und Gesundheitsdienstleistungen

Einfacher Zugang zu vertrauenswürdigen Behandlungen und Gesundheitsdiensten online.

Common conditions

Get help with common conditions through the NHS, without a GP appointment.

Book your free Pharmacy First appointment